Integer Holdings Corporation (ITGR)
| Market Cap | 3.03B -27.0% |
| Revenue (ttm) | 1.86B +6.3% |
| Net Income | 141.80M +84.4% |
| EPS | 3.97 +82.2% |
| Shares Out | 33.95M |
| PE Ratio | 22.50 |
| Forward PE | 14.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365,277 |
| Open | 90.00 |
| Previous Close | 90.00 |
| Day's Range | 89.13 - 90.52 |
| 52-Week Range | 62.00 - 123.78 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 97.22 (+8.89%) |
| Earnings Date | Apr 30, 2026 |
About ITGR
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, impl... [Read more]
Financial Performance
In 2025, Integer Holdings's revenue was $1.85 billion, an increase of 7.98% compared to the previous year's $1.72 billion. Earnings were $102.81 million, a decrease of -14.25%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ITGR stock is "Buy." The 12-month stock price target is $97.22, which is an increase of 8.89% from the latest price.
News
Oppenheimer upgrades Integer to Outperform as checks suggest PE CMO interest
As previously reported, Oppenheimer analyst Suraj Kalia upgraded Integer (ITGR) to Outperform from Perform with a $115 price target The firm notes Integer recently announced a strategic review process...
Integer upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Integer (ITGR) to Outperform from Perform with a $115 price target
Integer Holdings Transcript: Bank of America Global Healthcare Conference 2026
Outsourcing remains the dominant trend, with strong industry positioning and a diversified portfolio supporting growth. Strategic review is underway due to heightened interest, with a decision expected in months. Guidance was lowered mainly due to short-term EP inventory adjustments, but robust pipeline and margin improvement initiatives support confidence in long-term outperformance.
Integer price target lowered to $89 from $92 at Citi
Citi lowered the firm’s price target on Integer (ITGR) to $89 from $92 and keeps a Neutral rating on the shares.
Integer price target raised to $98 from $91 at BofA
BofA analyst Craig Bijou raised the firm’s price target on Integer (ITGR) to $98 from $91 and keeps a Neutral rating on the shares. Despite the Q1 revenue beat, the…
Integer initiates strategic review
Integer (ITGR) announced that its board of directors has initiated a strategic review. In consultation with its financial and legal advisors, the board will consider a full range of potential…
Integer Holdings Earnings Call Transcript: Q1 2026
Q1 2026 results met expectations with modest sales growth but lower margins and EPS. 2026 guidance was revised downward due to temporary headwinds in electrophysiology and risk adjustments, while a strategic review was launched amid increased external interest.
Integer Holdings Slides: Q1 2026
Integer Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Integer Holdings Earnings release: Q1 2026
Integer Holdings released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Integer Holdings Quarterly report: Q1 2026
Integer Holdings has published its Q1 2026 quarterly earnings report on April 30, 2026.
Integer Holdings Corporation Reports First Quarter 2026 Results
~ First quarter results in line with February outlook ~ ~ Updates 2026 outlook ranges; continues to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, April 30, 2026 (GLOBE NEWSWI...
Integer Announces Strategic Review to Maximize Stockholder Value
PLANO, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced ...
Integer to Participate in Bank of America Healthcare Conference on May 12
PLANO, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced participation ...
Integer chair Pamela Bailey to step down, Donald Spence to succeed
Integer (ITGR) announced Pamela Bailey, who currently serves as Integer’s independent chair of the board, will not stand for re-election at the company’s 2026 annual meeting of stockholders, scheduled...
Integer Announces Board Leadership Transition
PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced ...
Integer Holdings Proxy statement: Proxy filing
Integer Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Integer Holdings Proxy statement: Proxy filing
Integer Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Integer Announces Conference Call to Discuss First Quarter 2026 Results
PLANO, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), announced today ...
Integer Holdings Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management highlighted a smooth CEO transition, ongoing board refreshment, and a strategy focused on customer success and operational excellence. Temporary headwinds from three underperforming products are expected to subside by late 2026, with above-market growth targeted for 2027, driven by new product launches and a strong pipeline.
Integer Holdings Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management reaffirmed its strategy, focusing on organic growth, tuck-in M&A, and resilience to macro shocks. Despite a $70M headwind from three products in 2026, robust pipeline growth and new launches are expected to drive above-market performance by 2027.
Integer enters cooperation agreement with Irenic Capital Management
Integer (ITGR) Holdings Corporation announced that James Flanagan has been appointed to the Board of Directors as an independent director. Additionally, in connection with a cooperation agreement with...
Integer Appoints James Flanagan and Aaron Kapito to Board of Directors
~ Enters into Cooperation Agreement with Irenic Capital Management ~ PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contr...
Integer Holdings Transcript: 47th Annual Raymond James Institutional Investor Conference
A diversified MedTech manufacturer highlighted robust growth, a strong pipeline in high-growth markets, and disciplined capital allocation. Despite isolated 2026 headwinds from three products, the company expects to return to above-market growth in 2027, supported by new launches and a resilient business model.
Integer Holdings Slides: 47th Annual Raymond James Institutional Investor Conference
Integer Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
Law Offices of Howard G. Smith Announces Investigation of Integer Holdings Corporation (ITGR) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Integer Holdings Corporation (“Integer” or the “Company”...